The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma investment; Argentina’s ongoing struggle with COVID-19; issues around unchecked use of an anti-parasite drug; and the seismic economic and social impact of upcoming cannabis legalisation in Mexico.
Six Indian drug companies to set up a large pharma cluster in Mexico (The Economic Times of India)
A commerce ministry official said a couple of Indian drug makers have also agreed, in principle, to set up manufacturing facilities in Hidalgo to make Mexico their production and logistics hub and cater to Latin American regions.
Argentina passes 1 million COVID-19 cases as virus hits Latin America (AP)
As Argentina passed 1 million virus cases Monday, it is now smaller cities like Ushuaia that are seeing some of the most notable upticks. Doctors have had to quadruple the number of beds for COVID-19 patients over the last month. At least 60% of those tested recently are coming back positive for the virus.
Latin America’s embrace of an unproven COVID treatment is hindering drug trials (Nature)
Unchecked ivermectin use in the region is making it difficult to test the anti-parasite drug’s effectiveness against the coronavirus.
Mexico, plagued by cartel wars, on cusp of legal cannabis ‘green rush’ (Reuters)
For Guillermo Nieto, a Mexican businessman who grew up smoking pot, the cannabis greenhouse on his family’s vast farmlands in Guanajuato state is part of a bigger dream. One that involves deep-pocketed pharmaceutical companies.
Latin American populists push the economy over health (Australian Financial Review)
Lockdowns don’t work in poor countries, as populist leaders in Brazil and Mexico have discovered.
Govt invites LatAm, Caribbean nations to invest in India’s pharma sector (Business Standard)
Chemicals and Fertilisers Minister D V Sadananda Gowda on Wednesday invited Latin American and Carribean countries to invest in the Indian pharma sector, which he said could grow to become a USD 65 billion industry by 2024.